GLP1R and type 2 diabetes mellitus: Regarding the effect of GLP-1 RAs on MACE in T2DM patients of different races (Whites, Blacks, Asians, and others), in a metanalysis performed by Mei Qiu et al. (2020) on CVOTs of GLP-1 RAs it was found that GLP-1 RAs reduced the risk of MACE in all race subgroups with the exception of the Black race (0.92; 95% CI, 0.70–1.20; p < 0.05) [141].